Vironika, LLC, secured a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop small molecule Inhibitors to treat Human Immunodeficiency Virus (HIV).
This SBIR proposal addresses a critical need for therapeutics to supplement combination antiretroviral therapy (cART), which reduces viral load, but is unable to completely cure HIV-1 infection. The goal of this SBIR is to develop methods for identifying small molecules that result in inhibition of virus replication, which could lead to a functional cure of HIV disease.
"We are thrilled to have received funding to explore the development of new therapeutics with the potential to cure HIV infection," says Nelson Delgado, Ph.D., D(ABMM), Principal Investigator for this SBIR grant.
Vironika, LLC, is a privately held company founded in 2009 by Paul Lieberman, Ph.D. Dr. Lieberman is a full Professor at the Wistar Institute in Philadelphia.